Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Similar documents
New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

New York. Prescribing and Dispensing Profile. Research current through November 2015.

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015.

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Proposed Revision to Med (i)

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

CODE OF RHODE ISLAND RULES

MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012

Understanding Maine s Medical Marijuana Law

Prescription Monitoring Program (PMP)

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

State, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP

Policy \ \ Medical (Palliative) Use of Marijuana

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Rule Governing the Prescribing of Opioids for Pain

Opioid Management of Chronic (Non- Cancer) Pain

CERTIFICATION OF ENROLLMENT ENGROSSED SUBSTITUTE SENATE BILL th Legislature 2007 Regular Session

OREGON MEDICAL MARIJUANA ACT

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

Policy / Drug and Alcohol-Free Workshops

SECTION PRESCRIPTIONS

Managing Medical Marijuana in Schools:

RULE-MAKING ORDER PERMANENT RULE ONLY. CR-103P (December 2017) (Implements RCW )

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

LEGAL ASPECTS of MEDICAL MARIJUANA Florida Nurse Practitioner Network Annual Conference September 17, 2018

THE GENERAL ASSEMBLY OF PENNSYLVANIA HOUSE BILL

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

Be it enacted by the People of the State of Illinois,

2016 Dr. Douglas H. Kay CPE Symposium

Appendix F Federation of State Medical Boards

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 1030

ENROLLED 2014 Legislature CS for CS for SB 1030, 1st Engrossed

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998

STATEMENT OF POLICY REGARDING MEDICAL MARIJUANA AND OSTEOPATHIC PHYSICIANS APPROVED SEPTEMBER 9, 2014

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

Legal Issues in Opioid Prescribing

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

Sub. S.B. 119 As Passed by the Senate

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

OCCUPATIONAL AND PROFESSIONAL LICENSING OPTOMETRIC PRACTITIONERS CONTINUING EDUCATION

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

States with Authority to Require Nonresident Pharmacies to Report to PMP

State, District, or Territory Criteria for Mandatory Query of PDMP

From heroin to medical marijuana: what districts need to know Megan Greulich, Staff Attorney Hot Topics in School Law October 5, 2016

Ahsan U. Rashid, M.D., F.A.C.P.

Senate File Introduced

Naloxone Access Statutes

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

F L O R I D A H O U S E O F R E P R E S E N T A T I V E S HJR

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Alberta WCB Policies & Information

OPIOID. Opioid Legislation FAQs NEED TO KNOW

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

What Cities Need to Know about the Arkansas Medical Marijuana Amendment ( AMMA ) 1

Ontario s Narcotics Strategy

ASSEMBLY APPROPRIATIONS COMMITTEE STATEMENT TO. ASSEMBLY COMMITTEE SUBSTITUTE FOR ASSEMBLY, No STATE OF NEW JERSEY DATED: APRIL 5, 2018

RULES AND REGULATIONS FOR PAIN MANAGEMENT, OPIOID USE AND THE REGISTRATION OF DISTRIBUTORS OF CONTROLLED SUBSTANCES IN RHODE ISLAND

Therapeutic Cannabis Law Physician Issues

ARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH

For female patients only: To the best of my knowledgei am NOT pregnant. Patients Initials:

Rhode Island Department of Health

Instructions for Applicants. Successful completion of this examination is required as one of the conditions for licensure in the State of Vermont.

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 964 SUMMARY

Arkansas Municipal League. What Cities Need to Know about the Arkansas Medical Marijuana Amendment

Lobbyist-in-a-Box: (VPhAT) created on 01/15 at 10:11

Guideline for the Rational Use of Controlled Drugs

Controlled Substance Prescribing and Diversion. Pamela Polk, R. Ph., Inspector DHEC Bureau of Drug Control

Michigan Opioid Legislation Hospital Compliance Checklist

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Within the Scope of Practice/Role of _X APRN RN LPN CNA ADVISORY OPINION PAIN MANAGEMENT GUIDELIINES

Medical Marijuana and Student Health. New England College Health Association Gordon H. Smith, Esq. October 30, 2014

Department of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA

TEXAS COMPASSIONATE-USE ACT

Workplace Issues Associated with Legalized Marijuana. James B. Yates, Esq., SHRM-SCP, SPHR

A Bill Regular Session, 2015 SENATE BILL 717

December 2018 Brief Explanation of Proposition 2 and Compromise Bill Passage

Naloxone Access Statutes

Colorado State Board of Medical Examiners Policy

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED FEBRUARY 8, 2016

The Legalization of Medical Marijuana and the Impact on the Workplace

Diane E. Hoffmann, J.D., M.S. University of Maryland School of Law

XV. DRUG-FREE WORKPLACE PROCEDURES XV-1

NC General Statutes - Chapter 90 Article 5E 1

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

201 KAR 9:270. Professional standards for prescribing or dispensing Buprenorphine-Mono-Product or Buprenorphine-Combined-with-Naloxone.

MEDICAL MARIJUANA AND HEALTH CARE FACILITIES

North Dakota Board of Pharmacy

Transcription:

Prescribing and Dispensing Profile Rhode Island Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. 1

Schedule II Prescribing Limitations (not related to pain clinics) Schedule II substances may only be dispensed on the written prescription of a practitioner May be dispensed on the faxed prescription of a practitioner in the following circumstances: A Schedule II narcotic substance to be compounded for direct administration to a patient via certain methods For residents of a long-term care facility or a patient in a hospice program May be dispensed on the oral prescription of a practitioner in an emergency situation The quantity must be limited to an amount to treat the patient during the emergency period Must be immediately reduced to writing Prescriber must deliver a written prescription to the pharmacy within seven days Schedule II prescriptions become void if not dispensed within 90 days of being originally written No more than a 30-day supply shall be dispensed at any one time May write up to three separate prescriptions for a one-month supply each Must be signed and dated on the date written Must include the earliest date on which the prescription may be filled Schedule II prescriptions must be maintained in a separate file Schedule II prescriptions may not be refilled Schedule III, IV and V Prescribing Limitations (not related to pain clinics) Pharmacist may dispense a one-time prescription refill of a Schedule III V substance without prescriber authorization in an emergency Limited to a 72-hour supply The medication must be essential to the maintenance of life or to the continuation of therapy of a chronic condition In the pharmacist s professional judgment, the interruption of the therapy might reasonably produce undesirable health consequences or may cause physical or mental discomfort Schedule III prescriptions may not be written for more than 100 dosage units and not more than 100 dosage units may be dispensed at one time Schedule IV and V prescriptions may be written for up to a 90-day supply No more than 360 dosage units may be dispensed at one time Schedule III V prescriptions may not be filled or refilled more than six months after originally issued or refilled more than five times 2

Miscellaneous Prescribing/Dispensing Requirements May not prescribe any controlled substance in Schedules II IV without first conducting an original physical exam of the person for whom the controlled substance is intended Prescriptions shall meet the following requirements: Full name and address of the patient Name, address, and, if required by law or rules of the board, DEA registration number of the prescriber Date of issuance Name, strength, dosage form, and quantity of drug prescribed Directions for use Refills authorized, if any Prescribing practitioner s signature Prescribing/Dispensing Limitations for Dentists No separate statutes or regulations related to prescribing/dispensing for dentists. Prescribing/Dispensing Limitations for Optometrists Amplified optometrists may use and prescribe pharmaceutical agents in the treatment of conditions of the human eye and its appendages May not prescribe Schedule III or hydrocodone-containing medications for a period exceeding 72 hours Pain Clinic/Pain Management Regulations Intractable pain means a pain state that persists beyond the usual course of an acute disease or healing of an injury or results from a chronic disease or condition that causes continuous or intermittent pain over a period of months or years Practitioner may prescribe, administer, or dispense controlled substances for the treatment of intractable pain, if the diagnosis and treatment has been documented in the patient s record Drug dependency or the possibility of drug dependency in and of itself is not a reason to withhold or prohibit prescribing, administering, or dispensing controlled substances for a therapeutic purpose The following requirements apply to pain management: The physician shall obtain, evaluate and document the patient s health history and physical examination in the health record prior to treating for chronic pain Documentation in the medical record shall state the objectives that will be used to determine treatment success, including, but not limited to: Any change in pain relief Any change in physical and psychological function Additional diagnostic evaluations or other planned treatments 3

Pain Clinic/Pain Management Regulations, cont d. Practitioner shall advise the patient of the following when prescribing opioids for the treatment of chronic pain: Adverse risks Tolerance and dependency Addiction, overdose or death if acute or long term use Acknowledgement that it is the patient s duty to safeguard all medications and keep them in a secure location and properly dispose of any unused medications A written treatment plan shall be used, beginning no later than 90 days after beginning treatment with an opioid medication or long-acting opioid medication, and shall be between the patient and physician, and may include the following: Patient s agreement to take medication at the dose and frequency prescribed with a specific protocol for lost prescriptions and early refills Reasons for which drug therapy may be discontinued Prescriptions shall be provided by one prescriber or a limited agreed upon group of practitioners Patient s agreement not to abuse alcohol or use other medically unauthorized substances Acknowledgement that violation of the agreement may result in action as deemed appropriate Request that drug screens be completed upon request Physician shall conduct periodic reviews at intervals not to exceed twelve months, wherein physician shall determine: Patient s adherence to treatment plan If pain, function, or quality of life have improved or diminished using objective evidence If continuation or modification of treatment is necessary based on the practitioner s evaluation of the patient Practitioner shall consider tapering, changing, or discontinuing treatment when: Function or pain doesn t improve after a trial period There is reason to believe there has been misuse, addiction, or diversion To qualify as a pain medicine or addiction medicine specialist, a physician shall meet one or more of the following: Board certified or board eligible by an American Board of Medical Specialties approved board in physical medicine and rehabilitation, neurology, neurosurgery, addiction medicine, or anesthesiology, or by the American Board of Pain Medicine, or board certified or board eligible by an American Osteopathic Association approved board in physical medicine and rehabilitation, neurology and psychiatry, anesthesiology, or neuromusculoskeletal medicine Possess a subspecialty certificate in pain medicine Possess a certification of added qualification in pain management or pain medicine or a certification of special qualification in rheumatology Completion of a minimum of three years of clinical experience in a chronic pain management and: Successful completion of at least 18 continuing education hours in pain management during the last two years At least 30% of the physician s current practice is the direct provision of pain management care or is in a multi-disciplinary pain clinic 4

Pain Clinic/Pain Management Regulations, cont d. Multi-disciplinary approach to treating chronic pain Other professionals such as chiropractors, acupuncturists, behavioral health providers, and physical therapists are examples of providers who can use their skills to help alleviate patient s chronic pain Practitioners shall consider referral to other professionals as clinically indicated, including: Patients self-escalating their doses, early refills, inadequate pain relief, co-existing morbidities, prior history of substance abuse or prior overdose The consideration and documentation of consideration for consultation threshold for adults is 120 mg morphine equivalent dose per day If practitioner prescribes a dosage that meets or exceeds that amount, he or she shall consider consultation with a pain medicine physician If no consultation is obtained, the reasons for not obtaining a consultation shall be noted in the patient s record Training or Education Requirements or Recommendations for Practitioners who Prescribe or Dispense Controlled Substances No specific statutes or regulations identified. Medical Marijuana or Controlled Substances Therapeutic Research Program Provisions This section deals only with the conditions that qualify a patient for the use of medical marijuana or a therapeutic research program and the attendant physician responsibilities. For complete information on state medical marijuana and therapeutic research programs, please visit the NAMSDL website at www.namsdl.org. Controlled Substances Therapeutic Research Act Program is limited to patients who are certified by a practitioner as being involved in a life-threatening or sense-threatening situation and who are not responding to conventional drug therapies or where these conventional therapies have proven effective but expose the patient to undesirable side effects Program is limited to patients who are certified by a practitioner as being involved in a life-threatening or sense-threatening situation and who are not responding to conventional drug therapies or where these conventional therapies have proven effective but expose the patient to undesirable side effects A practitioner shall not be subject to arrest, prosecution, or penalty in any manner, or denied any right or privilege, including, but not limited to, civil penalty or disciplinary action by a professional licensing board solely for providing written certifications or for otherwise stating that, in the practitioner s professional opinion, the potential benefits of the medical marijuana would likely outweigh the health risks for a patient 5

Medical Marijuana or Controlled Substances Therapeutic Research Program Provisions, cont d. Debilitating medical condition means: Cancer, glaucoma, positive status for human immunodeficiency virus, acquired immune deficiency syndrome, Hepatitis C, or the treatment of these conditions A chronic or debilitating disease or medical condition, or its treatment, that produces one or more of the following: cachexia or wasting syndrome; severe, debilitating, chronic pain; severe nausea; seizures, including but not limited to, those characteristic of epilepsy; or severe and persistent muscle spasms, including but not limited to, those characteristic of multiple sclerosis or Crohn's disease; or agitation of Alzheimer's Disease Any other medical condition or its treatment approved by the department Written certification means: Qualifying patient s medical records Statement signed by the practitioner stating that, in the practitioner s professional opinion, the potential benefits of the use of medical marijuana would likely outweigh the health risks for the qualifying patient Certification shall only be made in the course of a bona fide physician-patient relationship after the practitioner has completed a full assessment of the qualifying patient s medical history Shall specify the qualifying patient s debilitating medical condition or conditions PMP Requirements for Mandatory Registration and Access All practitioners shall, as a condition of the initial registration or renewal of the practitioner s authority to prescribe controlled substances, register with the PMP Physician shall review the PMP prior to starting a patient on any opioid for the treatment of pain For patients the practitioner is maintaining on continuous opioid therapy for pain for six months or longer, the practitioner shall review PMP information at least every twelve months Practitioner shall review the PMP prior to refilling or initiating opioid therapy with an intrathecal pump Opioid treatment programs must check the PMP for each new admission, at each annual physical, and prior to advancement to a new take-home phase Patient Referral to Treatment No specific statutes or regulations identified. 6

Board Guidelines Board of Medical Licensure and Discipline Minimum Standards for Authorizing Medical Marijuana, September 30, 2011 Authorization of medical marijuana card requires that the authorizing practitioner conduct the type of physical examination that meets the following criteria: Authorizing practitioner must establish and maintain a medical record for the qualifying patient as required In the case of patients who are treating with another practitioner, the authorizing practitioner must review the last twelve months of the patient s medical record Authorizing practitioner must have conducted and documented an acceptable physical examination that meets the minimal standards for all new patient exams Authorizing practitioner must have diagnosed or confirmed the diagnosis that meets acceptable disease categories Authorizing practitioner must examine the patient s response to conventional medical therapies and explain the risks and benefits of the use of marijuana to the qualifying patient Authorizing practitioner must be committed to the continual assessment of the patient and the patient s response to the use of marijuana Must be demonstrated through follow-up appointments, semi-annually at a minimum, before the card is renewed 7